Daily Roundup

YAL.ASX VR1.ASX RZI.ASX NEU.ASX BOT.ASX

Yancoal Reports Solid Q3 Results, Maintains Guidance

Yancoal Australia Ltd had a productive third quarter, reporting 15.8Mt of run-of-mine coal production and 12.3Mt of saleable coal on a 100% basis. The company achieved an impressive average realised coal price of A$140/t, comprising A$130/t for thermal coal and A$195/t for metallurgical coal. Yancoal finished the quarter with a strong cash balance of $1.8 billion.

Despite a 7% decrease in ROM coal production from the prior quarter, Yancoal's saleable coal output remained flat. Attributable saleable production dipped 2% to 9.3Mt, while attributable coal sales increased 31% to 10.7Mt as the company recovered volumes delayed by weather-related shipping disruptions.

Yancoal's safety performance also improved, with the 12-month rolling Total Recordable Injury Frequency Rate (TRIFR) decreasing to 5.71 from 6.32 in the previous quarter. The company maintained its full-year operational guidance, expecting attributable saleable production to be in the upper half of the 35-39Mt range, cash operating costs around the mid-point of A$89-97/tonne, and capital expenditure within the A$750-900 million guidance.

Looking ahead, Yancoal remains optimistic about the long-term outlook for coal demand beyond 2040, despite current market challenges. The company believes that a significant uplift in demand or a meaningful supply-side response is required for coal prices to recover, with the latter occurring slowly as some higher-cost producers have entered administration.

Vection Secures $1.5M in New AI Orders Across Multiple Industries

Vection Technologies has received $1.5 million in confirmed purchase orders for AI-driven enterprise projects across a diverse range of industries, including agritech, cybersecurity, automotive, real estate, healthcare, and public administration. These orders include both new and recurring contracts from new and existing clients, further expanding Vection's presence in key innovation-driven sectors.

The new contracts came from a variety of sales sources, with 55% representing new business, 33% from upselling to existing customers, and 12% from existing client renewals. Agritech (27%) and cybersecurity (28%) make up the largest share of the orders, followed by real estate (15%), healthcare (11%), and public administration (10%). These projects include enterprise software licences, integrations, and service agreements, generating multi-year recurring revenue and further contract expansion potential.

Approximately 45% of the total order value represents renewals and upselling of existing contracts, validating Vection's strong customer retention and expansion capabilities. The associated revenues are expected to be recognised throughout FY26, aligning with project delivery and service timelines.

Raiz Invest Reaches $2 Billion in Funds Under Management

Raiz Invest Limited (ASX:RZI) has reported a strong start to the 2026 fiscal year, reaching a major milestone with record Funds Under Management (FUM) of $2 billion, up 32.5% year-over-year. This growth was driven by continued expansion in Active Customers, which increased 8.0% year-over-year to 335,542, and the launch of new product offerings such as Raiz Lite and Raiz Academy.

Raiz Lite is a low-cost entry plan for first-time investors, while Raiz Academy is a new online education platform. These new initiatives, along with strategic partnerships with State Street Investment Management and KFC, have helped Raiz increase customer engagement and drive growth across its product suite.

The company is on track to deliver FY26 Underlying EBITDA in the range of $4.5 million to $5.5 million, reflecting the strong momentum in its business. Raiz's revised fee schedule has had minimal impact on the existing customer base, with Raiz Lite acting as an effective entry point for higher-value offerings.

Neuren Pharmaceuticals Receives FDA Fast Track Designation for NNZ-2591 in Phelan-McDermid Syndrome

Neuren Pharmaceuticals (ASX: NEU) has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for its drug candidate NNZ-2591 for the treatment of Phelan-McDermid syndrome (PMS), a rare genetic disorder with no approved treatments.

The Fast Track designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Neuren recently initiated the 'Koala' Phase 3 randomized double-blind placebo-controlled clinical trial evaluating NNZ-2591 in children aged 3 to 12 years with PMS, which is the first ever Phase 3 clinical trial for this condition.

In addition to the Fast Track designation for PMS, NNZ-2591 has also been granted Fast Track for Angelman syndrome and Pitt Hopkins syndrome, meaning Neuren now has Fast Track for this drug candidate across all three of these rare neurodevelopmental disorders. Neuren is developing new therapies to treat multiple serious neurological disorders that emerge in early childhood and have limited or no approved treatment options.

Botanix Pharmaceuticals Reports Strong Q1 FY26 Results

Botanix Pharmaceuticals continued to see momentum in the commercial launch of its lead product Sofdra (sofpironium) topical gel, 12.45%, during the first quarter of fiscal year 2026. Total prescriptions shipped grew by 50% from the previous quarter to 20,418, driving a 65% increase in Sofdra net revenue to $7.1 million.

The company's gross-to-net (GTN) ratio improved to 23% in Q1 FY26, up from 21% in the prior quarter, as Botanix derived additional efficiencies of scale and an increasing percentage of prescriptions received full private payor coverage. Botanix's operating cash outflow also improved significantly, decreasing 54% to $13.1 million.

Botanix has a strong balance sheet with $49.2 million in cash and $15.2 million in undrawn debt as of 30 September 2025. The company has successfully completed the planned sales force expansion from 27 to 50 sales professionals and expects the strong growth in Sofdra sales to continue in Q2 FY26 and accelerate in Q3 FY26. Botanix aims to achieve an average GTN ratio in the range of 30%-40% over time, in line with successful US dermatology pharmaceutical companies.